Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 19.38% | Add +12.9% | 3,775,000 | $14.76 | $56M | +431,183 | +$15M |
| TELA - Tela Bio | 8.29% | Add +1.8% | 2,072,813 | $11.50 | $24M | +36,262 | +$6M |
| RYTM - Rhythm Pharmaceuticals | 7.44% | Reduce −9.3% | 735,000 | $29.12 | $21M | −75,000 | +$2M |
| OCUL - Ocular Therapeutix | 5.94% | Reduce −6.0% | 6,075,000 | $2.81 | $17M | −390,000 | −$10M |
| CRNX - Crinetics Pharmaceuticals | 4.66% | Add +9.0% | 732,000 | $18.30 | $13M | +60,700 | +$212K |
| CYTK - Cytokinetics | 3.98% | Reduce −4.9% | 250,000 | $45.82 | $11M | −13,000 | −$1M |
| Keros Therapeutics | 3.97% | Reduce −25.9% | 238,000 | $48.02 | $11M | −83,300 | −$658K |
| PCVX - Vaxcyte | 2.95% | Reduce −6.8% | 177,000 | $47.95 | $8M | −13,000 | +$4M |
| BHVN - Biohaven | 2.61% | New | 540,000 | $13.88 | $7M | +540,000 | +$7M |
| FDMT - 4D Molecular Therapeutics | 2.55% | Reduce −5.9% | 330,000 | $22.21 | $7M | −20,700 | +$5M |
| Protara Therapeutics | 2.51% | Reduce −0.6% | 2,692,594 | $2.68 | $7M | −15,473 | −$777K |
| Tracon Pharmaceuticals | 2.38% | Add +9.5% | 4,590,000 | $1.49 | $7M | +400,000 | −$158K |
| LRMR - Larimar Therapeutics | 2.24% | Reduce −6.1% | 1,560,000 | $4.13 | $6M | −101,784 | +$1M |
| Kalvista Pharmaceuticals | 2.17% | New | 923,200 | $6.76 | $6M | +923,200 | +$6M |
| ETON - Eton Pharmaceuticals | 2.13% | Reduce −13.9% | 2,170,000 | $2.82 | $6M | −351,000 | +$825K |
| EWTX - Edgewise Therapeutics | 1.90% | Reduce −3.7% | 611,400 | $8.94 | $5M | −23,600 | −$782K |
| PRQR - Proqr Therapeutics | 1.88% | Reduce −53.1% | 1,460,000 | $3.70 | $5M | −1,655,000 | +$3M |
| PHAT - Phathom Pharmaceuticals | 1.63% | New | 417,500 | $11.22 | $5M | +417,500 | +$5M |
| XOMA - XOMA Del | 1.55% | Reduce −2.0% | 243,000 | $18.40 | $4M | −5,000 | +$29K |
| CDXS - Codexis | 1.55% | Reduce −17.1% | 957,500 | $4.66 | $4M | −197,500 | −$3M |
| URGN - Urogen Pharma | 1.51% | Add +22.9% | 488,656 | $8.87 | $4M | +91,156 | +$1M |
| Karyopharm Therapeutics | 1.49% | New | 1,206,841 | $3.55 | $4M | +1,206,841 | +$4M |
| CATBUSD - Astria Therapeutics | 1.36% | Add +96.0% | 261,703 | $14.89 | $4M | +128,203 | +$3M |
| LQDA - Liquidia | 1.24% | Reduce −0.6% | 560,000 | $6.37 | $4M | −3,500 | +$502K |
| ZNTL - Zentalis Pharmaceuticals | 1.17% | New | 167,500 | $20.14 | $3M | +167,500 | +$3M |
| Marinus Pharmaceuticals | 1.14% | New | 826,200 | $3.98 | $3M | +826,200 | +$3M |
| Edap Tms S A | 1.14% | Add +330.2% | 306,713 | $10.66 | $3M | +235,413 | +$3M |
| WHWK - Aadi Bioscience | 1.12% | New | 252,046 | $12.83 | $3M | +252,046 | +$3M |
| Morphosys AG | 1.12% | Add +640.9% | 896,600 | $3.58 | $3M | +775,585 | +$3M |
| Mersana Therapeutics | 0.94% | Reduce −48.9% | 460,000 | $5.86 | $3M | −440,300 | −$3M |
| Theseus Pharmaceuticals | 0.93% | Add +142.5% | 535,000 | $4.98 | $3M | +314,350 | +$1M |
| Fennec Pharmaceuticals | 0.91% | New | 272,200 | $9.60 | $3M | +272,200 | +$3M |
| IDYA - Ideaya Biosciences | 0.88% | Add +9153.3% | 138,800 | $18.17 | $3M | +137,300 | +$2M |
| STXS - Stereotaxis | 0.85% | Reduce −23.9% | 1,185,000 | $2.07 | $2M | −371,800 | −$349K |
| BCABGBP - Bioatla | 0.75% | New | 261,800 | $8.25 | $2M | +261,800 | +$2M |
| Fortress Biotech | 0.47% | Reduce −31.6% | 2,050,000 | $0.6550 | $1M | −949,000 | −$1M |
| Allakos | 0.45% | Hold | 153,500 | $8.42 | $1M | — | — |
| Theravance Biopharma | 0.34% | New | 87,600 | $11.22 | $983K | +87,600 | +$983K |
| TRVI - Trevi Therapeutics | 0.33% | New | 485,000 | $1.93 | $936K | +485,000 | +$936K |
| Modular Medical | 0.17% | Reduce −11.0% | 245,000 | $2.00 | $490K | −30,422 | −$645K |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Cutera | 2.78% | Exit | 0 | $45.60 | $7M | −147,700 | −$7M |
| Inhibrx | 2.17% | Exit | 0 | $17.95 | $5M | −292,700 | −$5M |
| Merus | 2.09% | Exit | 0 | $20.03 | $5M | −253,200 | −$5M |
| Graphite Bio | 0.76% | Exit | 0 | $3.17 | $2M | −577,250 | −$2M |
| Impel Pharmaceuticals | 0.51% | Exit | 0 | $4.87 | $1M | −255,250 | −$1M |
| Chimerix | 0.29% | Exit | 0 | $1.93 | $704K | −365,000 | −$704K |
| DERM - Journey Medicine | 0.26% | Exit | 0 | $2.46 | $638K | −259,293 | −$638K |
| Neuropace | 0.18% | Exit | 0 | $3.75 | $436K | −116,324 | −$436K |
| Lumos Pharma | 0.17% | Exit | 0 | $8.85 | $412K | −46,576 | −$412K |
| Neoleukin Therapeutics | 0.15% | Exit | 0 | $0.6400 | $368K | −575,000 | −$368K |
| Optinose | 0.14% | Exit | 0 | $3.66 | $333K | −90,970 | −$333K |
| MGTX - Meiragtx | 0.03% | Exit | 0 | $8.40 | $84K | −10,000 | −$84K |
| Biolinerx | 0.01% | Exit | 0 | $0.9600 | $16K | −16,667 | −$16K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2